Over the past years the explanation of the hypercalcaemia associated with malignancy has changed repeatedly. Theories 
incidences of hypercalcaemia despite similar rates of bone metastases, c.f. squamous cell and small cell carcinoma of the lung. That certain malignancies might produce a humoral factor was suggested by the work of Gordan, Cantino, Erhardt et al. (1966) (Mundy, DeMartino & Rowe, 1981) .
Evidence began to emerge that the hypercalcaemia associated with non-metastatic malignancy could, occasionally, be completely corrected by treatment of the primary tumour. Furthermore, the biochemical changes present in such patients closely resembled those of primary hyperparathyroidism (Stewart, Horst, Deftos et al. 1980 ). This information suggested the production of a humoral agent by the primary tumour, and the possibility that it might be parathyroid hormone (PTH) was raised. (Skrabenek, McPartlin & Powell, 1980 (Assoian, Grotendorst, Miller & Sporn, 1984) and may be a common product of HHM tumour cells (Deuel, Huang, Strobant & Waterfield, 1983 (Docherty & Heath, 1987) . Last year Rabbani, Mitchell, Roy et al. (1986) published the purification of PTH-like factors from human and rat sources, so it seems that the full identity of this agent or agents will be known within the next year. The evidence for the role of PTH-like factors in HHM is again largely circumstantial, but the isolation of tumour products with PTH bioactivity from a patient who had overt 'parathyroid' bone disease is highly suggestive that the PTH-like factors were the aetiological agents in that patient's metabolic disorder (Loveridge et al. 1985) . Of particular relevance to this argument is the discovery of a PTH-like factor produced by non-transformed, human keratinocytes in culture (Merendino, Insogna, Milstone et al. 1986 
